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The TSG101 Tumor Susceptibility Gene
Is Located in Chromosome 11 Band p15 and
Is Mutated in Human Breast Cancer
Limin Li,* Xu Li,† Uta Francke,*† et al., 1993; Winqvist et al., 1993; Weitzel et al., 1994;
Baffa et al., 1996). We analyzed transcripts from 15and Stanley N. Cohen*
*Department of Genetics uncultured primary human breast carcinomas and
matched normal breast tissue from the same patients†Howard Hughes Medical Institute
Stanford University School of Medicine by RT–PCR, Southern blot analysis, and direct DNA se-
quencing and found that seven breast cancers had intra-Stanford, California 94305–5120
genic TSG101 deletions that physically or functionally
disrupted sequences encoding the coiled-coil domain
of the protein. Analysis of genomic DNA, which wasSummary
available from six of the seven patients showing muta-
tions in TSG101 transcripts, confirmed the presence ofRecent work has identified a mouse gene (tsg101)
abnormalities at the TSG101 genomic locus in all sixwhose inactivation in fibroblasts results in cellular
cancers. Mutations in two TSG101 alleles were identi-transformation and the ability to produce metastatic
fied by both genomic DNA analysis and cDNA analysistumors in nude mice. Here, we report that the human
in three breast cancers, and by cDNA analysis in a fourthhomolog, TSG101, which we isolated and mapped to
tumor. No TSG101 abnormalities were observed in tran-chromosome 11, bands 15.1–15.2, a region proposed
scripts or genomic DNAof matched normal breast tissueto contain tumor suppressor gene(s), is mutated at
from these breast cancer patients. Our findings indicatehigh frequency in human breast cancer. In 7 of 15
that TSG101 is mutated at high frequency in humanuncultured primary human breast carcinomas, intra-
breast cancer and further suggest that defects ingenic deletions were shown in TSG101 genomic DNA
TSG101 occur during breast cancer tumorigenesis and/and transcripts by gel and sequence analysis, and mu-
or progression.tations affecting two TSG101 alleles were identified in
four of these cancers. No TSG101 defects were found
in matched normal breast tissue from the breast can- Results
cer patients. These findings strongly implicate TSG101
mutations in human breast cancer. Cloning and Characterization of Human
TSG101 cDNA
tsg101 was initially identified in mouse cells by a novelIntroduction
gene-discovery approach (Random HomozygousKnock
Out [RHKO]) that enables regulated functional inactiva-tsg101 is a recently discovered tumor susceptibility
gene whose functional knockout in mouse fibroblasts tion of multiple copies of previously unknown genes and
selection for cells that show a phenotype resulting fromleads to transformation and the ability to form metastatic
tumors in nude mice (Li and Cohen, 1996). The cellular such inactivation (Li and Cohen, 1996). Using the 1448
bp mouse cDNA sequence to query the dbEST (Ex-transformation and tumorigenesis that result from inacti-
vation of tsg101 is reversible by restoration of tsg101 pressed Sequences Tags) database of the National Cen-
ter for Biotechnology Information (NCBI) by the BLASTfunction, suggesting that tsg101 acts to suppress malig-
nant cell growth. Sequence analysis of mouse tsg101 program, ten human partial cDNA sequences that
showed 85%–95% identity to mouse tsg101 cDNA werecDNA indicates that the gene encodes a 43 kDa protein
containing a proline-rich domain and DNA-binding mo- detected (Figure 1Aa). Primers corresponding to a se-
quence contained within a region of identity betweentifs characteristic of transcription factors. Additionally,
the TSG101 protein encodes a coiled-coil domain that ESTs H53754 and Z30135 (Pa-UDG and Pd-UDG) (Figure
1Ab) and to sequences bracketing the vector cloninginteracts with stathmin (Sobel, 1991), also known as
oncoprotein 18 (Marklund et al., 1993), a cytoplasmic site of a lgt10-based human cDNA library were used to
amplify by PCR the 59 (Pc-UDG and Pd-UDG) and 39 (Pa-phosphoprotein elevated in a variety of malignancies
and implicated in the regulation and relay of diverse UDG and Pb-UDG) segments of human TSG101 cDNA,
employing total cDNA from the library as template (Fig-signals associated with cell growth and differentiation
(Hanash et al., 1988; Sobel, 1991; Brattsand et al., 1993; ure 1Ab). The longest 59 and 39 PCR products were then
joined in the UDG cloning vector pAMP1.Roos et al., 1993).
We report here the cloning and mapping of the human A 1494 bp cloned human cDNA insert (tentatively
termed “full-length” TSG101 cDNA), which was 86%TSG101 gene and the occurrence of TSG101 mutations
in human breast cancer. Fluorescence in situ hybridiza- identical to mouse tsg101 cDNA at the nucleotide level,
contained a 1140 bp open translational reading frametion (FISH), radiation hybrid mapping, and analysis of
somatic cell hybrids localized TSG101 to human chro- predicted to encode a 380 amino acid protein with a
molecular mass of 42.841 kDa and a pI of 5.87 (Figuremosome 11, subbands p15.1–15.2, a region showing
loss of heterozygosity (LOH) in a variety of human malig- 1B). The predicted mouse and human proteins are 94%
identical and are distinguished by 20 amino acid mis-nancies, primarily breast cancers (e.g., Ali et al., 1987;
Winqvist et al., 1993) and proposed previously to contain matches and one gap (Figure 1B). A coiled-coil domain
(human TSG101 aa 231–302) and a proline-rich regiontumor suppressor gene(s) (Ali et al., 1987; Dowdy et al.,
1991; Ludwig et al., 1991; Seizinger et al., 1991; Lothe, (human TSG101 aa 130–205; 32% proline) typical of the
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Figure 1. Cloning and Sequence of Human TSG101 cDNA
(A) Cloning strategy. Partial human cDNA ESTs showing 85–95% identity to mouse tsg101 cDNA (see text) are shown (a). UDG primers Pa-
UDG and Pd-UDG employed a 27 bp sequence within a region of 100% identity between ESTs H53754 and Z30135. These, plus two other
UDG primers (Pb-UDG and Pc-UDG) corresponding to sequences bracketing the vector cloning site of a lgt10-based human placenta cDNA
library (ATCC), were used to amplify by PCR the 59 (Pc-UDG and Pd-UDG) and 39 (Pa-UDG and Pb-UDG) segments of human TSG101 cDNA
(b) using total DNA isolated from a human cDNA library as template. The longest 59 and 39 PCR products were joined in the UDG cloning
vector pAMP1.
(B) Human and mouse TSG101 protein sequence alignment. Amino acid sequences of the human and mouse TSG101 proteins were predicted
from TSG101 and tsg101 cDNA open reading frames determined by cDNA sequence analysis. The positions of mismatches and a gap between
human and mouse TSG101 are indicated with shaded minus sign (2). The predicted coiled-coil domain is shaded, and the amino acid positions
defining a leucine zipper motif within the coiled-coil domain are boxed. N-terminal to the coiled-coil domain is a proline-rich domain shown
by the amino acid designation for proline (P) in bold type.
activation domain of transcription factors (Mitchell and 38, 210, 249, 265, and 290), and three potential N-glyco-
sylation sites (aa 44, 150, and 297). Analysis of the hu-Tjian, 1989) are highly conserved between human and
mouse TSG101, with only one amino acid mismatch in man TSG101 cDNA and protein sequences by a BLAST
program search of the NCBI databaseshowed nosignifi-each of the two domains. The leucine zipper motif in
the coiled-coil domain of the human TSG101 protein is cant homology to any other known human gene se-
quence.identical to the one in the mouse protein (Figure 1B).
Other features conserved between human and mouse A multiple-tissue Northern blot probed with full-length
TSG101 cDNA showed a single 1.5 kb transcript in allTSG101 include seven putative protein kinase C phos-
phorylation sites (aa 11, 38, 86, 89, 215, 225, and 357), eight human tissues tested (Figure 2). The size of this
transcript indicates that the 1494 bp cDNA clone wefive potential casein kinase II phosphorylation sites (aa
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Figure 2. Expression of TSG101 in Human Tissues
Multiple-tissue blots for Northern blot analysis were purchased from
Clontech. Blots contained 2 mg of polyadenylated RNA in each lane
and were hybridized with single-strand full-length TSG101 cDNA
probe. Following hybridization, blots were stripped and rehybridized
with a probe for human b-Actin mRNA as a control for loading.
The positions of molecular-length markers and of the TSG101 and
b-Actin transcripts are shown.
had isolated does, in fact, correspond to essentially full-
length native TSG101 mRNA.
Chromosomal Localization of Human
and Mouse TSG101 Genes
Two PCR primers that specifically amplify a sequence
from the 39-untranslated region of human TSG101 cDNA
(see Experimental Procedures) were used to analyze
genomic DNA from a panel of 18 human 3 Chinese
hamster hybrid cell lines. A 210 bp PCR product was
generated from DNA from human cells and from hybrid
cell lines that contained human chromosome 11, but
not from hamster DNA; it also was obtained from DNA
Figure 3. Chromosomal Localization of Human TSG101of a hybrid cell line (31–2A HAT) containing the short
(Top) Fluorescence in situ hybridization. Double chromatid signalsarm of chromosome 11 (11p), but not from a cell line
(indicated by open arrows) are present at a site corresponding tothat contained only the long arm (11q) (data not shown).
human chromosome 11, bands p15.2–p15.1.
By concordant segregation and by exclusion of all other (Bottom) Ideogram of human chromosome 11 (Francke, 1994) illus-
chromosomes, the human TSG101 gene was assigned trating the localization of human TSG101 by somatic cell hybrids
to chromosome arm 11p. (SCH), FISH, and radiation hybrid (RH) mapping. Distances between
the STS markers (in centiRays) and lod scores (in parentheses) wereScreening of a PAC library of human genomic DNA
calculated using a two-point linkage program.using the TSG101-specific forward and reverse primers
indicated in Experimental Procedures yielded two over-
lapping clones, PAC1 and PAC2, each containing an
insert 150 kb in length. These were shown to contain identified the position of this gene relative to polymor-
phic markers on the linkage map. Eleven of the 83 RHTSG101 human genomic DNAby Southern blotting using
a 59 human TSG101 cDNA fragment as probe. FISH of cell lines showed a positive signal (retention frequency
13.25%) that by two-point linkage analysis was foundeach PAC clone to human chromosome spreads gave
a signal on chromatids of both copies of chromosome to be closely linked to RH map Bin17 markers, and
specifically to sequence-tagged site (STS) markers11 in 20 metaphase cells analyzed (Figure 3A). Based
on the chromosomal R-banding pattern, TSG101 is as- D11S921 through D11S1308 (Figure 3B). Both D11S921
and D11S1308 are on the Whitehead Institute integratedsigned to chromosome 11 subbands p15.1–p15.2.
Radiation hybrid (RH) mapping using the Stanford G3 map and radiation hybrid map, and their physical posi-
tions correspond approximately to 11p15. A cluster ofhuman RH mapping panel independently demonstrated
the map location of the human TSG101 gene and also serum amyloid A (SAA) genes closely linked to these
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markers has been mapped physically to subband
11p15.1 (Sellar et al., 1994), placing TSG101 in the region
encompassed by subbands 11p15.1–15.2.
We also determined the map location for the mouse
tsg101 gene and found it to be consistent with assign-
ment of the human TSG101 gene to 11p15. PCR analysis
of a mapping panel of 22 mouse 3 rodent hybrid cell
lines using mouse gene–specific primers showed that
the PCR product was in complete concordance with the
presence or absence of mouse chromosome 7 in these
hybrid cell lines. All other mouse chromosomes were
excluded by at least three discordant hybrids (data not
shown). Given the known conserved syntenic regions
on human chromosome 11p and mouse chromosome
7, the location of the mouse gene supports the conclu- Figure 4. Deletions within TSG101 cDNA in Primary Breast Cancers
sion that the human and mouse cDNA sequences we (A) Primer sets used and sizes of RT–PCR products are shown in
cloned are true gene homologs. An attempt to place relation to a schematic map of full-length TSG101 cDNA.
(B) TSG101 cDNA deletions in human primary breast cancers.tsg101 on the mouse linkage map by typing an interspe-
TSG101 cDNA generated by RT–PCR from primary breast cancerscies backcross panel was not successful, as no differ-
(T) and matched normal breast tissues (N) from seven individualsence between C57BL/6 and Mus spretus patterns were
(patients P1–P7) harboring these cancers. Primers Pr3 and Pr4 (Fig-
detectable by single-strand conformational analysis ure 4) were used to detect normal-size TSG101 cDNA (1145 bp),
(SSCA) of PCR products. However, our human gene which was generated by RT–PCR from transcripts present in both
mapping data would predict that the mouse homolog tumors and normal tissues, as well as truncated cDNA fragments,
which resulted from transcripts found only in the breast cancers.is located on genetic map unit 23.5–24 of chromosome
Lane MK contains a molecular-size standard 1 kb ladder (Life Tech-7 in the vicinity of the SAA genes (Mouse Genome Data-
nologies, Inc.).base, 1996).
the TSG101 protein-coding region (Figure 4A), of tran-TSG101 Mutations in Human Breast Cancers
scripts from 15 primary breast cancers and matchedExtensive studies have shown deletion or loss of hetero-
normal breast tissue showed deletions in TSG101 tran-zygosity at or near the 11p15 band in a variety of human
scripts in seven of these tumors but no abnormality inmalignancies, primarily breast cancers (e.g., Ali et al.,
TSG101 transcripts from the normalbreast tissue (Figure
1987; Winqvist et al., 1993), but also Wilms’ tumor
4 and Table 1). Sequence analysis of the truncated cDNA
(Dowdy et al., 1991; Cowell et al., 1993) and ovarian and
fragments resulting from deletions in TSG101 tran-
testicular malignancies (Lothe et al., 1993; Weitzel et al.,
scripts and of the corresponding regions of transcripts
1994), suggesting that this region contains one or more
from each matched normal breast tissue specimen (Fig-
tumor suppressor gene(s) that are mutated or deleted
ure 5) indicated the sites of the deletion junctions and
in these cancers. Approximately 30% of 171 sporadic
consequently identified the endpoints of the deletions.
primary breast cancers analyzed showed loss of hetero- These are summarized in Table 1.
zygosity in a region mapping between 11p15.4 and The deletions occurring in the tumors of all breast
11pcen (Seizinger et al., 1991). The notion that the short cancers except P5 directly eliminated all or part of the
arm of chromosome 11 contains a tumor suppressor TSG101 transcript segment encoding the coiled-coil do-
gene implicated in the pathogenesis of human breast main, which is specified by nt 810–1022 of the transcript
cancer is further supported by evidence that introducing (Figure 1B). The deletion in P5 is predicted to remove
a normal chromosome 11 or segments of this chromo- 200 aa (codons 6–205) upstream from the coiled-coil
some into breast cancer cells reverses their metastatic domain and to generate, after codon 205, a frameshift
potential, as well as other properties associated with leading to premature termination of the TSG101 protein
oncogenesis (Koi et al., 1993; Negrini et al., 1995; Phillips one codon later. Three of the seven primary breast can-
et al., 1996). The finding that inactivation of tsg101 con- cers showing deletions in TSG101 transcripts produced
verts mouse fibroblasts into metastasizing cancer cells two different truncated transcript species, implying the
(Li and Cohen, 1996) indicates that this gene may func- occurrence of lesions in both TSG101 alleles in these
tion as a suppressor of malignant cell growth. Our map- cancer cells. Remarkably, identical 921 bp deletions as-
ping of human TSG101 to a region of chromosome 11 sociated with identical 63 bp insertions at the deletion
implicated in human breast cancer led us to investigate junctions were observed in transcripts from breast can-
a possible role for TSG101 in breast tissue malignancy. cers P4 and P7. Other transcripts encoded by tumor P7
We examined cDNA from 15 uncultured primary human included a 902 bp deletion in the same region, but lacked
breast cancers specifically for mutations in TSG101, the 63 bp insertion. The presence of both an insertion
comparing breast cancer transcripts (i.e., cDNA) and and a deletion in the same transcript suggests that multi-
breast cancer genomic DNA with transcripts and geno- ple mutational events may occur in TSG101 during tu-
mic DNA obtained from matched normal breast tissue morigenesis or progression of primary breast cancers.
from the same patients. Analogous evidence for multiple mutations or DNA re-
arrangements at the TSG101 locus was obtained forRT–PCR amplification, using primers that bracketed
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Table 1. Summary of cDNA and Genomic DNA Mutations in TSG101 Locus in Uncultured Primary Human Breast Cancer
Case/Typea RT–PCR Product(s) cDNA Sequence Genomic DNA
P1/Infiltrating ductal carcinoma Abnormal Deletion 153–1053 z13.6 kb deletion
(Age 40) Point mutation at bp
1162b
P2/Intraductal and invasive car- Abnormal Deletion A255–895 z11.4 kb deletion and
cinoma (Age 34) frame shift
Deletion B365–1216 z7.4 kb deletion
P3/Invasive ductal carcinoma Abnormal Deletion 153–1053 z14.8 kb deletion
(Age 70)
P4/Poorly differentiated ductal Abnormal Deletion A641–1158 z7.4 kb deletion
carcinoma (Age 75)
Deletion B133–1054 and 63 bp z14.4 kb deletion
insertion
P5/Infiltrating lobularcarcinoma Abnormal Deletion 132–729 z16.4 kb deletion and
(Age 65) frame shift
P6/Infiltrating ductal carcinoma Abnormal Deletion 153–1053 ND
(Age 65)
P7/Infiltrating ductal carcinoma Abnormal Deletion 133–1054 and 63 bp z12.2 kb deletionc
(Age 40) insertion
Deletion 153–1053 z12.2 kb deletion
Genomic DNA and cDNA obtained from 14 primary breast cancers and matched normal breast tissue from the same patients were analyzed,
and only cDNA was analyzed for a fifteenth breast cancer and matched normal control. The length of genomic DNA deletions was calculated
by subtracting the length of truncated TSG101 DNA, as detected by Southern blotting, from the chromosomal DNA distance between primers
Pr5 and Pr6 (determined as 15.4 Kb from the structure of the TSG101 genome locus) (Figure 7). The point mutation in the nondeleted allele
was identified by sequencing of the DNA fragment generated by PCR using primers Pr7 and Pr8, confirmed by the ablation of a BbsI restriction
endonuclease cleavage site as a result of the mutation (Figure 8).
a Surgical pathology diagnosis.
b The T-to-C mutation changing Val to Ala.
c The similarly-sized deleted genomic DNA bands for these two alleles were not distinguished, as noted in the text.
genomic DNA (see below). Nondeleted TSG101 tran- A search for point mutations in the coiled-coil region
of the nondeleted TSG101 alleles of tumors P1, P3, andscripts were also present in all of the primary breast
cancers we analyzed, consistent with the presence of P5 by sequencing of PCR-amplified exons 3, 4, and 5
of TSG101 genomic DNA (see Figure 7) using intronnontumor cells in these cancer specimens, as has been
described previously for other malignancies (e.g., Sozzi primers (see Experimental Procedures) showed a T-to-C
point mutation at bp position 1162 in the nondeletedet al, 1996).
Genomic DNA was available for 6 of the the 7 primary allele of P1 (Figure 7 and Table 1). This was identified
by sequencing the 375 bp PCR-amplified genomic DNAbreast cancers producing abnormal TSG101 transcripts.
Southern blotting of PCR-amplified genomic DNA from fragment. Restriction enzyme analysis of this fragment
confirmed the loss of a BbsI site, which was eliminatedall 6 breast cancers showed truncated TSG101-specific
DNA fragments resulting from genomic deletions that by the T-to-C transition, at the site of the mutation (Fig-
ure 8). As described above, tumor P7 produced twowere not present in DNA from matched normal breast
tissue from the same patients (Figures 6 and 7). While separate TSG101 transcript species containing dele-
tions (Figures 4 and 5; Table 1). While these deletionsthese truncated genomic DNA fragments were in most
instances of the size expected from deletion of exon were similar in length, one of the deleted transcripts
and intron sequences located between the endpoints had a 63 bp insertion identical to the insertion found
of the cDNA deletions we had mapped by gel analysis in transcripts of tumor P4. As the 3 kb PCR-amplified
and sequencing, in some tumors our genomic DNA anal- genomic DNA fragments generated in tumor P7 by these
ysis suggested that multiple deletions and/or insertions events were similar to each other in size, they were
had occurred at the TSG101 locus. not distinguished by gel analysis in the present studies.
Evidence of TSG101 mutations in both alleles was Thus, lesions in two TSG101 alleles were demonstrated
obtained by genomic DNA analysis for 3 of the 7 breast by both genomic DNA analysis and cDNA analysis for
cancers. The genomic DNA deletion in one allele of P4 three of the six primary breast cancers showing TSG101
was the size expected from the cDNA deletion end- abnormalities and by cDNA analysis in a fourth tumor.
points; mutation of the second allele produced two trun-
cated bands, suggesting that sequences within an intron
Discussionamplified by primers Pr5 and Pr6 (Figure 7), but external
to the deletion detected by the cDNA analysis (primers
The malignantchanges that result from functional inacti-Pr3 and Pr4, Figure 4A) were also absent or rearranged
vation of tsg101 in mouse fibroblasts previously impli-during tumorigeneis or progression of this cancer. In
cated the loss or disruption of tsg101 function in tumori-primary breast cancer P2, which had shown deletions
genesis (Li and Cohen, 1996). Our present results mapof two different lengths in TSG101 cDNA, genomic DNA
the human TSG101 gene to chromosome 11p15, a sitefragments of the sizes expected from cDNA analysis
were observed for both deletions. suspected to harbor tumor suppressor gene(s) involved
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Figure 5. Sequence at TSG101 cDNA Dele-
tion Junctions in Human Primary Breast
Cancers
The sequences of relevant regions of TSG101
cDNA from seven primary breast cancers (P1,
P2, P3, P4, P5, P6, and P7) and from the
corresponding segment of a DNA derived
from matched normal breast tissue (P1WT–
P7WT) are shown. The (A) and (B) designa-
tions refer to sequences of the two different
mutated cDNA species obtained from some
of these tumors. In each case, a panel show-
ing the sequence of the corresponding seg-
ment of TSG101 cDNA derived from matched
normal control tissue is shown adjacent to
the mutated sequence. Arrows indicate the
deletion junctions in tumor transcripts.
(Figure 5 continued on following page)
in a variety of human cancers, particularly breast cancer regulating cell proliferation and differentiation. All of the
TSG101 deletion mutations we identified removed all or(Seizinger et al., 1991; Bieche and Lidereau, 1995). They
further show that this gene and its transcripts are abnor- part of this domain, suggesting its relevance to theability
of TSG101 to suppress malignant cell growth. The pointmal in human breast cancer. No TSG101 abnormalities
were observed in transcripts or genomic DNA from mutation discovered at TSG101 bp 1162 in the nonde-
leted allele of tumor P1 is predicted to result in an aminomatched normal breast tissue from breast cancer pa-
tients. acid change from Val to Ala at one of the putative protein
kinase C phosphorylation sites of the TSG101 protein.Both the mouse and human TSG101 proteins contain
a coiled-coil domain nearly identical to one shown to The presence of DNA-binding motifs in the TSG101 pro-
tein and a proline-rich region near the leucine zipperinteract with stathmin (Maucuer et al., 1995), also known
as oncoprotein 18 (Marklund et al., 1993), a phosphopro- DNA-binding motif suggests that TSG101 may be a tran-
scription factor that is a downstreameffector of stathmintein proposed to coordinate and relay diverse signals
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(Figure 5 continued)
action. Whether a mutation in two TSG101 alleles, which conserved. Chromosomal mapping of TSG101 to human
chromosome 11 and mouse chromosome 7, which sharewas shown for genomic DNA of three of the breast can-
cers we studied and by cDNA analysis in a fourth, is conserved syntenic regions, supports the conclusion
that the human gene we have cloned is the true humanrequired for breast cancer tumorigenesis, or whether a
single coiled-coil domain–disrupting mutation can act homolog of mouse tsg101.
Frequent abnormalities at 11p15 have been identifiedin concert with a mutation in some other gene in breast
cancer, is not known. in human breast cancers (Ali et al., 1987; Mackay et al.,
1988; Ferti-Passantonopoulou et al., 1991; Chen et al.,The extraordinary conservation between the mouse
and human TSG101 proteins is consistent with the no- 1992; Miyagi et al., 1992; Takita et al., 1992; Winqvist et
al., 1993, 1995; Gudmundsson et al., 1995; Karnik et al.,tion that this gene, which was unknown until recently,
has an important biological role: the coiled-coil and pro- 1995; Negrini et al., 1995) and also in a variety of other
human cancers, including lung cancer (Ludwig et al.,line-rich domains are highly similar in the mouse and
human proteins, and additionally, the potential phos- 1991; Fong et al., 1994; Kondo, et al., 1994), testicular
cancer and male germ cell tumor (Lothe et al., 1993;phorylation and N-glycosylation sites are completely
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Studies of families showing early-onset breast cancer,
which represents 5–10% of all breast malignancies, have
led to the identification of two candidate breast cancer
suppressor genes, BRCA1 and BRCA2 (Miki et al., 1994;
Wooster et al., 1995). A role for these genes in the re-
maining 90–95% of (sporadic) breast cancers has not
been established, and accumulating evidence indicates
that mutations in the BRCA1 and BRCA2 genes are
infrequent in breast cancer cells themselves (Futreal et
al., 1994; Lancaster et al., 1996; Miki et al., 1996; Teng et
al., 1996). In contrast, genomic DNA deletions in TSG101
were detected by us in more than 40% of the primary
breast cancers we analyzed. The absence of detectable
TSG101 mutations in DNA from normal breast tissue
from patients that were the source of the primary breast
tumors we examined implies that deletion of TSG101
occurred during or following tumorigenesis and conse-
quently is not likely to be linked to familial breast cancer.
The current study has not investigated breast cancer–
prone families for possible abnormalities in TSG101.
All of the breast cancers we studied had metastasized,
although the tumors analyzed were obtained from the
primary site in human breasts. Breast cancer cell lines
lacking a DNA region that we now know contains the
TSG101 gene have been shown to have high metastatic
Figure 6. Southern Blot Analysis of PCR-Amplified Genomic DNA potential in nude mice (Zhang et al., 1991). This observa-
from Uncultured Primary Human Breast Cancers and Matched Nor- tion is consistent with the finding that LOH at 11p15 in
mal Breast Tissue
primary human breast cancers is associated with poor
The locations of primers Pr5 and Pr6 (see Figure 7) used for PCR
survival after tumor metastasis (Winqvist et al., 1995)amplification (approximately 15.4 kb apart in the wild type TSG101
and the suggestion that LOH at 11p15 may be involvedgenomic locus, as determined by analysis of a PAC clone containing
in late-stage tumor progression (Bieche and Lidereau,the locus) and of hybridization probes H2 (used for all tumors except
P2, which has the H2 segment of one allele completely deleted) and 1995). Interestingly, mouse fibroblasts that were trans-
H1 (used only for tumor P2, right panel) are shown in Figure 7. An formed by inactivation of tsg101 formed tumors in nude
MK 1 kb ladder was used as a size marker (see Figure 4), and the mice that metastasized to the lungs (Li and Cohen,
positions of marker bands are indicated. (T) indicates genomic DNA 1996), the principal site of metastases of human breast-
from primary breast cancers; (N) indicates genomic DNA from
cancer cells (Harris et al., 1993).matched normal breast tissue. Tumor P6 and normal tissue from this
The TSG101 gene and the protein it encodes may bepatient were unavailable for genomic DNA analysis. The presence
of comparable amounts of tumor-cell DNA and matched normal useful for not only the diagnosis of human breast cancer,
controls in each lane is demonstrated in the bottom panel, which and perhaps of other human cancers as well, but also
shows a Southern blot of a PCR-amplified 375 bp segment of exon for increasing understanding of basic mechanisms of
5 that is present in DNA from both normal cells and tumors. tumorigenesis and tumor progression.
Smith and Rukstalis, 1995), stomach cancer (Baffa et Experimental Procedures
al., 1996), Wilms’ tumor (Dowdy et al., 1991; Cowell et
al., 1993), ovarian cancer (Weitzel et al., 1994), bladder cDNA and Genomic DNA Cloning
Two UDG-primers (Booth et al., 1994) derived from ESTs H53754cancer (Presti et al., 1991; Brewster et al., 1994), myeloid
and Z30135 are Pa-UDG (59 AGGUCAUGAUUGUGGUAUUUGGAGleukemia (Nakamura et al., 1996), malignant astrocyto-
AUG 39) and Pd-UDG (59 CAUCUCCAAAUACCACAAUCAUGAmas and other primitive neuroectodermal tumors (Fults
CCU 39). Two UDG-primers derived from lgt10 cloning site are
et al., 1992), and infantile tumors of adrenal and liver Pb-UDG (59 CAUCAUCAUCAUGAGGTGGCTTATGAGTATTTCTTC
(Byrne et al., 1993). Since LOH is believed to indicate CAG 39) and Pc-UDG (59CUACUACUACUACACCTTTTGAGCAAGTT
CAGCCTGGTT39). 59 (Pc-UDG and Pd-UDG) and 39 (Pa-UDG andinactivation of a tumor suppressor gene at the location
Pb-UDG) segments were amplified by PCR as follows: 100 ml finalwhere LOH occurs, the frequent LOH found at 11p15 in
volume of 20 mM Tris-HCl pH 8.55, 3.3 mM MgCl2, 16mM (NH4)2SO4,multiple human cancers suggests the presence of either
150 mg/ml BSA, 300 mM each dNTP, 1 ml human placenta lgt10a cluster of tumor suppressor genes or a single tumor
cDNA library (titer 106/ml, ATCC), 0.2 ml of KlentaqLA (Barnes, 1994),
suppressor in this region (Seizinger et al., 1991). Chro- in a Perkin-Elmer/Cetus thermal cycler for 40 cycles of 958C for
mosome transfer studies have shown that chromosome 0.75 min for denaturation, and 728C for 1.0 min for annealing and
extension. The PCR products were visualized in ethidium bromide-11 can suppress tumorigenicity of both human breast
stained low melting agarose gels, purified, and cloned into thecancer (Negrini et al., 1995) and Wilms’ tumor cells
pAMP1 cloning vector (Life Technologies, Inc.). Multiple clones were(Dowdy et al., 1991), and a gene (named HTS1 or ST5)
isolated and both strands of thecDNA inserts were sequenced usingthat may be responsible for suppressing tumorigenicity
Sequenase 2.0 (USB).
in HeLa cells has been mapped to 11p15 (Lichy et al., The PCR product made using primers, 59 CTGATACCAGCTGGAG
1992). The sequence of the putative translation product GTTGAGCTCTTC 39 (forward primer) and 59 ATTTAGCAGTCCCAAC
ATTCAGCACAAA 39 (reverse primer) were used to screen a PACof this gene has no resemblance to TSG101.
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Figure 7. Endpoints of TSG101 Mutations in
Primary Breast Cancers
Schematic map of region of human genomic
DNA containing the TSG101 gene. The tenta-
tive genomic DNA structure of TSG101 was
determined from PAC 1 using the method de-
scribed by Riley et al, 1990 and Derry et al,
1995). The lengths and positions of exons
(numbered boxes) and the locations and ap-
proximate lengths of identified introns (hori-
zontal lines) are shown. The locations of prim-
ers Pr5 and Pr6 used for PCR amplification
of segments of TSG101 genomic DNA are
indicated, as are the locations of TSG101-
specific hybridization probes (H1 and H2)
used forSouthern blot analysis of PCR-ampli-
fied DNA. The fragments produced by geno-
mic DNA deletions are shown in Figure 6. The
positions shown here for exonic endpoints
of the deletions are based on the TSG101
genomic DNA structure and the TSG101
cDNA sequences determined for each tumor.
The 63 bp insertions found in the cDNA of
tumors P4 and P7 are shown schematically
by diagonal lines and are not drawn to scale.
library containing human genomic DNA inserts (Genome Systems, Chinese hamster and two mouse 3 rat somatic-cell hybrid lines
derived from four independent fusion experiments as describedInc.), yielding two overlapping clones, PAC1 and PAC2, each con-
taining inserts about 150 kb long. The presence of TSG101-specific previously (Li et al., 1993). The PCR primers used to amplify human
and murine TSG101/tsg101 sequences were derived from the 39sequences within these inserts was confirmed by Southern blotting,
using a 59 fragment of human TSG101 cDNA as probe. untranslated region: the human primers were those employed to
clone TSG101 genomic DNA (see above). The murine primers were:
59 GAGACCGACCTCTCCGTAAAGCATTCTT39 (forward primer) andPrimary Breast Cancers and Matched Normal Breast Tissue
Fourteen primary breast tumors and matched normal breast tissue 59 TAGCCCAGTCAGTCCCAGCACAGCACAG 39 (reverse primer).
PCR conditions were 958C for 2.0 min; then 35 cycles of 948C forfrom the same patients were obtained from Cooperative Human
Tissue Network (Eastern, Southern, and Western divisions). Breast 0.5 min; 688C for 0.5 min; 728C for 1.0 min; followed by 728C for 7.0
min To distinguish the PCR products from human and hamstercancer cDNA and cDNA from matched normal breast tissue for P6
were purchased from Biochain Institute, Inc. (San Leandro, CA). sequences in some of hybrid lines, SSCA was carried out as de-
scribed previously (Li et al., 1995b).
Multitissue Northern Blot Analysis of TSG101 Expression
A Northern blot filter containing mRNA isolated from normal human
tissues was purchased (Clontech). Radioactively-labeledsingle anti- TSG101 Gene Mapping
For fluorescence in situ hybridization, two genomic DNA clonessense strand DNA probe generated from full-length human TSG101
cDNA by 40 cycles of primer extension, using [32P]dCTP, was hybrid- (PAC1 and PAC2) carrying 150 kb inserts, each containing overlap-
ping human TSG101 sequences, were labeled with biotin-11-dUTPized to the filter using standard methods.The same blot was stripped
and hybridized with a human b-actin probe synthesized by random by nick translation using commercial reagents (Boehringer Mann-
heim). Probes were hybridized at a concentration of 200 ng/50 mlpriming as internal loading control.
per slide to pretreated and denatured metaphase chromosomes
from human lymphocytes, and signals were detected, amplified,Somatic Cell Hybrids, PCR Amplifications, and SSCA
The chromosome carrying the human TSG101 gene was identified and analyzed as described previously (Li, et al., 1995a).
The Stanford G3 radiation hybrid mapping panel consisting ofusing a panel of 18 human 3 Chinese hamster hybrid cell lines
derived from several independent fusion experiments (summarized 83 RH clones of the entire human genome with a resolution of
approximately 500 kb was purchased from Research Genetics, Inc.in Francke et al., 1986). The murine tsg101 gene was mapped to a
mouse chromosome by analyzing a mapping panel of 20 mouse 3 All 83 RH cell lines were typed for the human TSG101 gene by using
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and DNA fragments were cut from gels and purified using QIA quick
gel extract kit (Qiagen). The sequence of cDNA derived from primary
breast cancers and matched normal breast tissue was determined
using an Applied Biosystems model 310 genetic analyzer.
PCR Amplification of Genomic DNA
Genomic DNA was isolated by standard methods. 50 ng of RNase
A–treated genomic DNA was used as template for PCR amplifi-
cations. The primers used for analysis of genomic DNA were P5
(59 CTCTAGAGGATCCAGGCACCTTTTGAGCAA 39) and P6 (59 TTAC
TCAAATGCTTCAATTTCAAATATTTCAAA 39). Primer Pr7 (59 TTCCT
GTGAAGTGTTGTAGGTGTCTGA 39) and primer Pr8 (59 GGTCAGTG
CCTCTACAACCCAAGTTAA 39) were used for exon 5 amplification.
PCR amplifications were carried out using 50 ng RNase A–treated
genomic DNA in 50 ml final volume of 20 mM Tris–HCl [pH 8.55], 3.3
mM MgCl2, 16 mM (NH4)2SO4, 150 mg/ml BSA, 300 mM each dNTP,
0.2–1.0 ml of KlentaqLA (Barnes, 1994) in a Perkin-Elmer/Cetus ther-
mal cycler for 35 cycles at 958C for 0.25 min (for denaturation) and
688C for 2.0–5.0 min (for annealing and extension).
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